BIOAVAILABILITY OF IRON AND CYANIDE FROM ORAL POTASSIUM FERRIC HEXACYANOFERRATE(II) IN HUMANS

被引:22
作者
NIELSEN, P
DRESOW, B
FISCHER, R
HEINRICH, HC
机构
[1] Abteilung Medizinische Biochemie, Physiologisch-Chemisches Institut Universitätskrankenhaus Eppendorf, Hamburg 20, 2000
关键词
Cyanide bioavailability; Hexacyanoferrates(II); Iron absorption; Radiocaesium;
D O I
10.1007/BF01973468
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
After oral administration of 500 mg KFe[Fe(CN)6] labelled with59Fe either in the ferric or ferrous position and with14C in the cyanide group only 0.22% of the FeII and <0.04% of the FeIII were absorbed in three male volunteers. Only 2 mg non-complex bound relabelled cyanide (0.03 mg CN-/kg body wt) were absorbed from 500 mg [14C]KFeHCF, which is about a factor of 20-100 below the lethal dose in humans (0.5-3.5 mg CN-/kg body wt). Therefore, iron(III) hexacyanoferrates(II) can be considered as safe antidotes, i.e. for inhibiting the intestinal absorption of radiocaesium or for accelerating the excretion of already absorbed134/137Cs in the case of a severe nuclear accident. © 1990 Springer-Verlag.
引用
收藏
页码:420 / 422
页数:3
相关论文
共 21 条
[1]  
BAUMEISTER RGH, 1975, ARZNEIMITTEL-FORSCH, V25, P1056
[2]   INTERNAL DOSE FROM C-14-LABELED COMPOUNDS - METABOLISM OF C-14-LABELED POTASSIUM CYANIDE IN RAT [J].
CRAWLEY, FEH ;
GODDARD, EA .
HEALTH PHYSICS, 1977, 32 (03) :135-142
[3]  
DAGG JH, 1966, CLIN SCI, V30, P495
[4]  
DRESOW B, 1990, IN PRESS Z NATURFORS
[5]  
Dvorak P, 1970, Arzneimittelforschung, V20, P1886
[6]   METABOLIC BEHAVIOUR OF COLLOIDAL FERRIHEXACYANOFERRATE(II) [J].
DVORAK, P ;
GUNTHER, M ;
ZORN, U ;
CATSCH, A .
NAUNYN-SCHMIEDEBERGS ARCHIV FUR PHARMAKOLOGIE, 1971, 269 (01) :48-&
[7]   BINDING BY HEXACYANOFERRATES(II) OF THALLIUM(I) [J].
DVORAK, P .
ZEITSCHRIFT FUR NATURFORSCHUNG PART B-CHEMIE BIOCHEMIE BIOPHYSIK BIOLOGIE UND VERWANDTEN GEBIETE, 1971, B 26 (04) :277-&
[8]  
GIESE W, 1970, ZENTRALBLATT VETER S, V11, P185
[9]  
HAVLICEK F, 1967, STRAHLENTHER ONKOL, V134, P123
[10]  
HEINRICH HC, 1965, ATOMPRAXIS, V11, P430